Thomas Ciulla MD PC

[ad_1] PEACHTREE post hoc analysis: Significant reduction of macular edema, low rate of rescue in patients with chronic uveitis https://t.co/bU3e1GaYVW via @modernretina [ad_2] Source by Thomas Ciulla, MD, MBA Return to main website.

[ad_1] RT @Ophthalmologymg: In his article, “Suprachoroidal Injections: Xipere and Beyond,” Mark R. Barakat, MD, discusses how targeting the supra… [ad_2] Source by Thomas Ciulla, MD, MBA Return to main website.

[ad_1] RT @ModernRetina: Rahul Khurana, MD, offers updates and details about the Aaviate study, which is investigating a possibly once-and-done ge… [ad_2] Source by Thomas Ciulla, MD, MBA Return to main website.

[ad_1] RT @Biotech_Winners: Clearside Biomedical Suprachoroidal Delivery Technology to be Featured at Upcoming ASRS and OIS Medical Meetings https… [ad_2] Source by Thomas Ciulla, MD, MBA Return to main website.

[ad_1] RT @ThomasCiullaMD: Our clinical study, highlighting the need for better therapy, was picked up by Ophthalmology Advisor: Longer Term Anti-… [ad_2] Source by Thomas Ciulla, MD, MBA Return to main website.

[ad_1] Looking forward to discussing #drugdelivery and durability at OIS ASRS! #OIS #retina https://t.co/kkYEiiIS5r [ad_2] Source by Thomas Ciulla, MD, MBA Return to main website.

[ad_1] RT @ModernRetina: Survey respondents point to a perceived gap in treatments for uveitic macular edema, document interest in suprachoroidal… [ad_2] Source by Thomas Ciulla, MD, MBA Return to main website.